Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individuals

Journal of Acquired Immune Deficiency Syndromes

Volumn 58, Issue 5, 2011, Pages 450-457

  Jackson, Akil ^a   Watson, Victoria ^b,c   Back, David ^b   Khoo, Saye ^b   Liptrott, Neill ^b,c   Egan, Deidre ^b,c   Gedela, Keerti ^a   Higgs, Chris ^a   Abbas, Riaz ^d   Gazzard, Brian ^a   Boffito, Marta ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^d Janssen Cilag Ltd   (United Kingdom)

Author keywords

darunavir ritonavir; drug interactions; intracellular pharmacokinetics; raltegravir

Indexed keywords

ABACAVIR; DARUNAVIR PLUS RITONAVIR; EMTRICITABINE; LAMIVUDINE; RALTEGRAVIR; TENOFOVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

ADULT; ANTI-HIV AGENTS; AREA UNDER CURVE; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PYRROLIDINONES; RITONAVIR; SULFONAMIDES; YOUNG ADULT;

EID: 81755184134     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182364c67     Document Type: Article

References (22)

1. Ford J, Khoo SH, Back DJ. The intracellular pharmacology of antiretroviral protease inhibitors. J Antimicrob Chemother. 2004;54: 982-990. (Pubitemid 40136729)
2. Bazzoli C, Jullien V, Le Tiec C, et al. Intracellular pharmacokinetics of antiretroviral drugs in HIV-infected patients, and their correlation with drug action. Clin Pharmacokinet. 2010;49:17-45.
3. Khoo SH, Hoggard PG, Williams I, et al. Intracellular accumulation of human immunodeficiency virus protease inhibitors. Antimicrob Agents Chemother. 2002;46:3228-3235.
4. Crommentuyn KM, Mulder JW, Mairuhu AT, et al. The plasma and intracellular steady-state pharmacokinetics of lopinavir/ritonavir in HIV-1-infected patients. Antivir Ther. 2004;9:779-785. (Pubitemid 39434342)
5. Breilh D, Pellegrin I, Rouzes A, et al. Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR study). AIDS. 2004;18:1305-1310. (Pubitemid 38822709)
6. Ford J, Boffito M, Maitland D, et al. Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients. J Antimicrob Chemother. 2006;58:1009-1016.
7. Fletcher CV, Kawle SP, Kakuda TN, et al. Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIVinfected persons. AIDS. 2000;14:2137-2144.
8. Owen A, Khoo SH. Intracellular pharmacokinetics of antiretroviral agents. J HIV Ther. 2004;9:97-101.
9. Boffito M, Miralles D, Hill A. Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naive and-experienced patients. HIV Clin Trials. 2008;9:418-427.
10. Ter Heine R, Mulder JW, van Gorp EC, et al. Intracellular and plasma steady-state pharmacokinetics of raltegravir, darunavir, etravirine and ritonavir in heavily pre-treated HIV-infected patients. Br J Clin Pharmacol. 2010;69:475-483.
11. Fayet Mello A, Buclin T, Franc C, et al. Cell disposition of raltegravir and newer antiretrovirals in HIV-infected patients: high inter-individual variability in raltegravir cellular penetration. J Antimicrob Chemother. 2011;66:1573-1581.
12. Wang L, Soon G, Goh B, et al. Time-course comparison of intracellular and plasma raltegravir after a single dose in healthy volunteers. Presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 15, 2011; Boston, MA.
13. Molto J, Valle M, Back D, et al. Plasma and intracellular (peripheral blood mononuclear cells) pharmacokinetics of once-daily raltegravir (800 milligrams) in HIV-infected patients. Antimicrob Agents Chemother. 2011;55:72-75.
14. Boffito M, Acosta E, Burger D, et al. Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugs. Antivir Ther. 2005; 10:469-477. (Pubitemid 41059193)
15. Garvey L, Latch N, Erlwein OW, et al. The effects of a nucleosidesparing antiretroviral regimen on the pharmacokinetics of ritonavirboosted darunavir in HIV type-1-infected patients. Antivir Ther. 2010; 15:213-218.
16. Eron J, Rockstroh J, Reynes J, et al. QDMRK, a Phase III study of the safety and efficacy of once daily vs twice daily RAL in combination therapy for treatment-naïve HIV-infected patients. Presented at: 18th Conference on Retroviruses and Opportunistic Infections; March 2, 2011; Boston, MA.
17. Benech H, Theodoro F, Herbet A, et al. Peripheral blood mononuclear cell counting using a DNA-detection-based method. Anal Biochem. 2004;330:172-174. (Pubitemid 38746990)
18. Else L, Watson V, Tjia J, et al. Validation of a rapid and sensitive highperformance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds. J Chromatogr B Analyt Technol Biomed Life Sci. 2010;878:1455-1465.
19. Taiwo B, Zheng S, Gallien S, et al. Results from a single arm study of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). Presented at: 18th Conference on Retroviruses and Opportunistic Infections; March 2, 2011; Boston, MA.
20. Bedimo R, Drechsler H, Turner D, et al. RADAR study: raltegravir combined with boosted darunavir has similar safety and antiviral efficacy as tenofovir/emtricitabine combined with boosted darunavir in antiretroviralnaive patients. Presented at: 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 2011; Rome, Italy.
21. Watson V, Liptrott N, Egan D, et al. Investigating variability in reported intracellular raltegravir concentrations: contribution of PBMC isolation methodology. Presented at: 12th International Workshop on Clinical Pharmacology of HIV Therapy; April 14, 2011; Miami, FL.
22. Arab-Alameddine M, Fayet-Mello A, Lubomirov R, et al. Population pharmacokinetic analysis and effects of raltegravir in HIV positive and healthy individuals. Presented at: 12th International Workshop on Clinical Pharmacology of HIV Therapy; April 15, 2011; Miami, FL.